Literature DB >> 2297824

Role of adenosine in pathogenesis of anginal pain.

F Crea1, G Pupita, A R Galassi, H el-Tamimi, J C Kaski, G Davies, A Maseri.   

Abstract

The intravenous infusion of adenosine provokes anginalike chest pain. To establish its origin, an intracoronary infusion of increasing adenosine concentrations was given in 22 patients with stable angina pectoris. During adenosine infusion, 20 patients had chest pain without electrocardiographic signs of ischemia. They all reported that the chest pain was similar to their usual anginal pain. In 10 of the 22 patients adenosine was also infused into the right atrium, but it never produced symptoms at the doses that had provoked chest pain during intracoronary infusion. In seven other patients, the intracoronary adenosine infusion was repeated after intravenous administration of aminophylline, an antagonist of adenosine P1-receptors. Aminophylline decreased the severity of adenosine-induced chest pain (assessed with a visual analog scale) from 42 +/- 22 to 23 +/- 17 mm (p less than 0.002). In the remaining five of the 22 patients, monitoring of blood oxygen saturation in the coronary sinus during intracoronary adenosine administration showed that maximum coronary vasodilation was achieved at doses lower than those responsible for chest pain. A single-blind, placebo-controlled, randomized trial of the effect of aminophylline on exercise-induced chest pain was also performed in 20 other patients with stable angina. Aminophylline, compared with placebo, decreased the severity of chest pain at peak exercise from 67 +/- 21 to 51 +/- 23 mm (p less than 0.02), despite the achievement of a similar degree of ST-segment depression. Finally, the effect of intravenous adenosine was compared in 10 patients with predominantly painful myocardial ischemia and in 10 patients with predominantly silent ischemia.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2297824     DOI: 10.1161/01.cir.81.1.164

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  26 in total

1.  Effect of oral aminophylline in patients with angina and normal coronary arteriograms (cardiac syndrome X).

Authors:  P M Elliott; K Krzyzowska-Dickinson; R Calvino; C Hann; J C Kaski
Journal:  Heart       Date:  1997-06       Impact factor: 5.994

2.  Effects of L-arginine on flow mediated dilatation induced by atrial pacing in diseased epicardial coronary arteries.

Authors:  D Tousoulis; G J Davies; C Tentolouris; T Crake; G Goumas; C Stefanadis; P Toutouzas
Journal:  Heart       Date:  2003-05       Impact factor: 5.994

Review 3.  Cardiac purinergic signalling in health and disease.

Authors:  Geoffrey Burnstock; Amir Pelleg
Journal:  Purinergic Signal       Date:  2014-12-20       Impact factor: 3.765

Review 4.  Silent myocardial ischemia: recent developments.

Authors:  Peter F Cohn
Journal:  Curr Atheroscler Rep       Date:  2005-03       Impact factor: 5.113

Review 5.  Clinical and periprocedural pain management for uterine artery embolization.

Authors:  Elizabeth Brooke Spencer; Peter Stratil; Heidi Mizones
Journal:  Semin Intervent Radiol       Date:  2013-12       Impact factor: 1.513

6.  Role of endogenous adenosine in vasovagal syncope.

Authors:  M Sinkovec; A Grad; P Rakovec
Journal:  Clin Auton Res       Date:  2001-06       Impact factor: 4.435

Review 7.  Pharmacological rationale for the clinical use of caffeine.

Authors:  J Sawynok
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

Review 8.  The therapeutic and diagnostic cardiac electrophysiological uses of adenosine.

Authors:  A D Malcolm; C J Garratt; A J Camm
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

9.  Usefulness of stellate ganglion block for refractory angina pectoris.

Authors:  Jason Chung-Chieh Lo; David Nguyen; T Keller Matthews
Journal:  Proc (Bayl Univ Med Cent)       Date:  2018-05-09

10.  An irreversible A1-selective adenosine agonist preconditions rabbit heart.

Authors:  G S Liu; K A Jacobson; J M Downey
Journal:  Can J Cardiol       Date:  1996-05       Impact factor: 5.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.